SD-SAB-BIO/CSL-BEHRING
7.1.2020 15:38:13 CET | Business Wire | Press release
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into multiple collaboration and option agreements with global biotherapeutics leader CSL Behring. The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb™ platform.
SAB has developed a unique platform, through advanced genetic engineering, to naturally and rapidly produce large amounts of human antibodies without using human donors.
The agreement includes a research program which will investigate a potential new source for human immunoglobulin G (IgG). Human IgG is currently used for a number of immunological and neurological diseases including Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), and Multifocal Motor Neuropathy (MMN).
CSL Behring is a leader in the global immunoglobulins market, which has grown substantially over the last five years. Key factors fueling market growth include an aging population, increased emphasis on the diagnosis and treatment of immune diseases, and its increased use in new indications.
“SAB Biotherapeutics has developed a very interesting and novel platform for the production of human immunoglobulins,” said Dr. Andrew Nash, Senior Vice President, Research for CSL Behring. “CSL Behring is committed to the continuous development of innovative therapies that address unmet needs for patients with rare and serious diseases. This collaboration will provide both companies an opportunity to explore the potential of these new approaches to positively impact areas of need.”
CSL Behring’s R&D footprint includes more than 1,700 scientists across the globe with an R&D investment exceeding $800 million in 2018 - 2019.
“We are excited that CSL Behring has chosen to work with SAB Biotherapeutics to explore new immunotherapies leveraging our technology platform,” said Dr. Eddie J. Sullivan, president, CEO and co-founder of SAB Biotherapeutics. “We believe combining our unique human antibody development and production capabilities with CSL Behring’s established immunoglobulin franchise and vast expertise in biopharmaceutical development will broaden therapeutic possibilities.”
CSL Behring and SAB will share research program and related costs and plan to complete the initial phase in 2020. The collaboration may lead to subsequent development and commercialization agreements.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB), headquartered in Sioux Falls, S.D. is a clinical-stage, biopharmaceutical development company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, highly targeted, high-potency, immunotherapies at commercial scale. The company is advancing programs in autoimmunity, infectious diseases, inflammation and exploratory oncology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005718/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DATA Launches GCC Innovation Acceleration Program to Support Innovation Creation by Global Companies16.3.2026 04:30:00 CET | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the launch of its GCC Innovation Acceleration Program. This is designed to support global companies rapidly establishing and scaling their strategic offshore hubs in India, including Global Capability Centers (GCC) and other innovation and delivery hubs. Launched in October 2025, the program aims to support more than 50 companies over the next three years. The demand for highly skilled IT personnel has expanded globally, and as a result, companies are increasingly using overseas bases to meet innovation needs. NTT DATA identified India as a stand-out market to launch the GCC Innovation Acceleration Program because of its abundance of talent and strong technical capabilities. India’s Global Capability Center ecosystem, delivering IT services and back-office functions to multinationals, is poised for strong growth of nearly 70%, targeting $110 billion in 2030 from the current $65 billion, according
OXMIQ Labs and AM Intelligence Labs Partner to Architect One of the World’s Largest Renewable-Powered AI Compute Platforms16.3.2026 01:50:00 CET | Press release
Optimizing from photons to outcomes. Powered by 100% renewable energy. OXMIQ Labs (“OXMIQ”), the GPU architecture and AI technology company founded by Raja Koduri, today announced a strategic technology partnership with AM Intelligence Labs, a business division of AM Group, to provide data center and system infrastructure advisory for AM Intelligence Labs' 2 GW AI Compute Capability by 2030 with initial 1 GW AI Compute Hub in Uttar Pradesh, India. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260315355703/en/ OXMIQ and AM Intelligence Labs are building one of the world's largest renewable-powered AI compute platforms - 2 Gigawatts by 2030, Phase 1 online in Noida, India by 2027. AM Intelligence Labs is a strategic business division of AM Group, parent of Greenko, India's largest green energy producer with 50 GW of renewable capacity across solar, wind, and hydro, backed by 100 GWh of intelligent energy storage and supplying
4th Digital Engineering Awards Celebrate Global Innovators, AI Trailblazers: Herald the Rise of Engineering Intelligence14.3.2026 17:46:00 CET | Press release
Developed in association with ISG and CNBC-TV18, the fourth edition draws more than 250 nominations from 90+ global companies The Digital Engineering Awards concluded its fourth edition at Boston, Massachusetts on Thursday, honoring technology pioneers and organizations for their contributions to technology solutions and AI advancements. The gala night presented by L&T Technology Services (BSE: 540115, NSE: LTTS) along with ISG as the knowledge and research partner and CNBC-TV18 as the media partner, hosted both industry leaders and individual changemakers from 17 countries across North America, Europe, and the rest of the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260314443410/en/ The 4th edition of the Digital Engineering Awards, in association with ISG, CNBC-TV18 and L&T Technology Services, drew more than 250 nominations from 90+ global companies A total of 258 nominations from leading organizations and engine
Venture Global Announces Final Investment Decision and Financial Close for Phase 2 of CP2 LNG13.3.2026 15:23:00 CET | Press release
$8.6 billion project financing for CP2 Phase 2 brings project’s total financing to $20.7 billionProject expected to make Venture Global the largest exporter of US LNGUnprecedented milestone of five FIDs in less than 7 years, with over $95 billion in capital markets transactions Today, Venture Global, Inc. (NYSE: VG) is announcing a final investment decision (FID) and successful closing of an $8.6 billion project financing for the second phase of the company’s third project, Venture Global CP2 LNG (CP2). When combined with the Phase One financing for CP2 announced July 2025, this milestone represents the largest standalone project financing in the U.S. bank market.The transaction garnered enormous interest from the world’s leading banks, resulting in over $19 billion of commitments for Phase Two in addition to the previous $34 billion of commitments for Phase One, and required no outside equity investment. “We are extremely proud to have taken FID on the second phase of CP2, our third g
NIQ Launches Beta of New AI-Powered Analytical Capabilities in Ask Arthur13.3.2026 12:00:00 CET | Press release
AI-guided analysis helps brands and retailers turn data into decision-ready insights NIQ (NYSE: NIQ), a global leader in consumer intelligence, has launched new AI-powered analytical capabilities in beta within Ask Arthur on the NIQ Discover platform. The expanded experience guides users through end-to-end analysis—helping them identify what matters in the data, understand why trends are occurring, and turn insights into clear, shareable narratives with recommended next steps. As organizations navigate increasing data complexity, the ability to move quickly from insight to action has become essential. Ask Arthur helps shorten analytical processes that once took days or weeks into minutes by surfacing the key drivers behind performance changes and generating decision-ready insights directly within Discover. By connecting analysis, explanation, and storytelling in a single experience, users can move seamlessly from understanding what is happening in the data to determining what to do nex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom